SCHEMBL4302874

SCHEMBL4302874

O=[N+]([O-])c1c(Cl)c2cccnc2n2nnnc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
MAPT P10636 6/20 0.37
LMNA P02545 6/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TLR9 Q9NR96 2/20 0.37
XBP1 P17861 1/20 0.37
PAX8 Q06710 1/20 0.37
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
HTT P42858 4/20 0.36
KDM4E B2RXH2 4/20 0.36
TDP1 Q9NUW8 4/20 0.36
HSP90AA1 P07900 2/20 0.36
OPRK1 P41145 2/20 0.36
BRD4 O60885 1/20 0.36
CTSB P07858 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3354370 0.84 S100A4 (0.42) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL3355530 0.84 NPY1R (0.36) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL6106397 0.81 ALDH1A1 (0.51) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL13914465 0.78 MAPT (0.37) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL7025149 0.76 MAPT (0.38) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL12701776 0.76 KDM4E (0.32) ALDH1A1MAPTLMNASMN1; SMN2NPSR1
SCHEMBL13588384 0.76 CYP1A2 (0.32) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL1895900 0.75 MAPT (0.36) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL14419217 0.75 LMNA (0.34) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL10237130 0.75 PDE4D (0.37) ALDH1A1MAPTLMNASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS IL2, IL4I1, IFNG ALDH1A1 821/4885MAPT 3772/4885LMNA 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.